Market Overview
Ticagrelor,
a potent platelet aggregation
inhibitor, has been a significant player in the pharmaceutical market. Its
mechanism of action involves reversibly binding to the P2Y12 receptor on
platelets, thereby inhibiting their aggregation and reducing the risk of
thrombotic events in patients with acute coronary syndromes. This unique
mechanism distinguishes Ticagrelor from other antiplatelet agents, making it a
cornerstone in the management of cardiovascular diseases. The market for
Ticagrelor has witnessed substantial growth due to its proven efficacy and safety
profile in various clinical trials, establishing it as a preferred choice for
clinicians worldwide.
As
the demand for effective antiplatelet therapies continues to rise, Ticagrelor
occupies a prominent position in the market landscape. Its widespread adoption
is fueled by robust research supporting its role in improving clinical outcomes
in patients with acute coronary syndromes. Furthermore, the development of
novel formulations and combination therapies incorporating Ticagrelor further
expands its market potential. With increasing awareness about the importance of
platelet inhibition in preventing cardiovascular events, the Ticagrelor market
is poised for continued growth, offering new opportunities for pharmaceutical
companies to innovate and meet the evolving needs of patients with
cardiovascular diseases.
The
global ticagrelor market size is
predicted to grow USD 3.32 billion by 2032 a striking CAGR 6.4% during the
forecast period 2023-2032 owing to the rising patient population suffering from
heart problems, asserts Market Research Future (MRFR).
Drivers and Constraints Impacting the Market
The
global ticagrelor market is estimated to register a healthy CAGR due
to several driving factors. With increasing patient population suffering from
heart problems, the market is estimated to foster during the assessment
period.Increasing product developmentby the companies, funding for research and
development activities by the major market players, and improving market access
scenarios are further estimated to propel the market. Moreover, owing to the
presence of several well-established players, the ticagrelor market is
estimated to flourish in the coming years.
On
the flip side, side effects of ticagrelor such as chest pain, irregular
heartbeat, shortness of breath, nose bleeding, and spots under the skin are
some of the major concerns considered to impede the market growth during the
estimated period.
Competitive Dashboard
The
global ticagrelor market
companies are
- Alexion,
- Ingelheim,
- Roche,
- Ingelheim
Pfizer,
- Pfizer,
- GSK,
- Boehringer,
- Amgen,
- Boehringer,
- Merck,
- Amgen,
and
- Eli
Lilly.
Global Ticagrelor Market: Segmental Analysis
The
global ticagrelor market has been segmented on the basis of end-users and
region.
By
mode of end-users, the global ticagrelor market has been segmented into
hospitals, clinics, and medical institutions. Among these, the hospital segment
is considered to experience a significant growth rate during the assessment
period owing to the well-developed infrastructure and latest devices offered by
the hospitals. Moreover, rising incidences of heart attacks are propelling the
segment growth.
Regional Insights
Geographically,
the ticagrelor market span across regions namely, Europe, Americas,Asia
Pacific, and the Middle East & Africa.
Among
all the regions, America occupies the largest market share of approx. more than
40% owing to the extensive use of the drug by the patients who are discharged
from hospitals in this region. Moreover, presence of major manufactures in this
region is further contributing to the market growth.
Europe
is estimated to be the second largest market and is anticipated to maintain its
dominance during the appraisal period owing to the increasing awareness of
ticagrelor in this region. Moreover, well-developed hospital infrastructure has
further promoted the market growth.
The
Asia Pacific region is considered to expand at the fastest growth rate owing to
the increased number of cardiovascular patients in this region. Economies such
as China and India are predicted to be the fastest growing regions. Moreover,
major key players are expanding their presence in this region which is further
contributing to the market growth. For instance, Sun Pharmaceutical Industries
Ltd.and AstraZeneca Pharma India Limited had announced that they had entered
entered into a distribution services agreement in India for Axcer, which is a
new brand of ticagrelor.
On
the other hand, the Middle East & Africa is presumed to occupy the least
market share owing to poor medical facilities, lack of awareness, and limited
market scenario activities.
Related
Reports-
For more information, Please Visit us @ Market Research Future
